How the EU Pharmaceutical Strategy could help prevent the next pandemic

21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

read more >>

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

read more >>

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

​20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

read more >>

AMR: The life of innovative SMEs

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

read more >>

Latest news of BEAM Alliance

25 November 2021 - BEAM Alliance

Antimicrobial Resistance Campaign 2021

Antimicrobial Resistance Campaign 2021. The needs of SMEs must be considered when reshaping the regulatory framework in AMR innovation.

read more >>

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

read more >>

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

​20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

read more >>

21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

read more >>

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

read more >>

07 September 2021 - BEAM Alliance

Antimicrobial resistance: ​the silent pandemic

It is necessary to support R&D with ad hoc funding (so-called PUSH incentives), but above all to set up market…

read more >>

page 1/5

next

Twitter

View twitter feed

Latest news of BEAM Members

10 January 2022 - Aptorum Group Ltd

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel first-in-class orally administered small molecule drug based…

read more >>

10 January 2022 - Da Volterra

Da Volterra Announces the Publication of Positive Results from the SHIELD Phase 2 Clinical Trial Evaluating DAV132 in Patients in the Journal of Antimicrobial Chemotherapy

The company’s lead product-candidate, DAV132, is the world’s most advanced product protecting against the clinical consequences of microbiome dysbiosis: it…

read more >>

06 January 2022 - DEINOVE

DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections

The DSMB considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the clinical trial.…

read more >>

06 January 2022 - ANTABIO S.A.S

French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance

Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project…

read more >>

30 December 2021 - Polyphor Ltd

Polyphor closes merger with EnBiotix and is renamed Spexis

Headquartered in Switzerland and Boston, two global biotech-hubs, our ambition is to develop Spexis into a leading biopharmaceutical company with…

read more >>

15 December 2021 - Polyphor Ltd

Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inhaled murepavadin

Polyphor is a research-oriented Swiss biopharmaceutical company with a leading macrocyclic peptide technology platform. Polyphor is headquartered in Allschwil near…

read more >>

page 1/34

next

Events

07 April 2022

6th AMR Conference

The AMR conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and…

read more >>

28 March 2022

BIO-Europe Spring 2022: 16th Annual International Partnering Conference delivered In-Person & Digitally

The sixteenth annual BIO-Europe Spring® conference will bring together the life science community for global dealmaking in-person and digitally.

read more >>

14 February 2022

4th Bacteriophage Therapy Summit

The definitive gathering of global phage experts across disciplines and industries is back. Focusing on human health and disease, advance…

read more >>

26 January 2022

Human – Animal One Health: At the Confluence of human & veterinary public health

«The One Health Concept: At the confluence of human and veterinary public health» aims to bring together researchers, industrial stakeholders and…

read more >>

26 January 2022

REVIVE Webinar: New technologies and strategies to overcome the challenges of sexually transmitted infections

REVIVE is a space for everybody with an interest in antimicrobial R&D.

read more >>

19 January 2022

REVIVE Webinar: Target candidate profiles and target product profiles for new antimicrobials

REVIVE is a space for everybody with an interest in antimicrobial R&D.

read more >>

10 January 2022

Biotech Showcase 2022 (In-person & Virtual Event)

Engage with Global investors & Life Sciences Executives! Join us from January 10–12, 2022 in San Francisco, or Join us…

read more >>

09 December 2021

SCT Virtual Symposium: On the hunt for next generation antimicrobial agents

An exciting two-day symposium entitled: On the hunt for next generation antimicrobial agents. This symposium will bring together some of…

read more >>

23 November 2021

Phage futures Europe: Translating phage-based applications into clinically and commercially viable therapeutics

Seeing the news that Proteon Pharmaceuticals secured a €21 million investment was an exciting moment. It is another backing in…

read more >>

page 1/12

next